ReviewClinics (Sao Paulo, Brazil)2012
Temozolomide in aggressive pituitary adenomas and carcinomas.
Review in Clinics (Sao Paulo, Brazil), 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 53 citations in OpenAlex.
- Deep-Red and Near-Infrared Compact Cyanine Dyes for Sensitive NAD(P)H Sensing in Live Cells and Kidney Disease Tissues.ACS applied bio materials · 2024Article
- Aggressive prolactinoma (Review).Experimental and therapeutic medicine · 2022Review
- Pituitary carcinoma: Two case reports and review of literature.World journal of clinical oncology · 2020Article
- Pediatric Pituitary Adenoma: Case Series, Review of the Literature, and a Skull Base Treatment Paradigm.Journal of neurological surgery. Part B, Skull base · 2018Review
- Pituitary-Directed Therapies for Cushing's Disease.Frontiers in endocrinology · 2018Review
- Pituitary Carcinoma in a Patient with an SDHB Mutation.Endocrine pathology · 2017Article
- How effective is temozolomide for treating pituitary tumours and when should it be used?Pituitary · 2017Review
- Temozolomide therapy in patients with aggressive pituitary adenomas or carcinomas.Journal of neuro-oncology · 2016Article
- Treatment of invasive silent somatotroph pituitary adenoma with temozolomide. Report of a case and review of the literature.Endocrine pathology · 2015Review
- Temozolomide-Induced Shrinkage of Invasive Pituitary Adenoma in Patient with Nelson's Syndrome: A Case Report and Review of the Literature.Case reports in endocrinology · 2015Article
- Peptide receptor radionuclide therapy for aggressive atypical pituitary adenoma/carcinoma: variable clinical response in preliminary evaluation.Pituitary · 2014Article
- Systemic therapy of Cushing's syndrome.Orphanet journal of rare diseases · 2014Review
- Aggressive pituitary adenomas--diagnosis and emerging treatments.Nature reviews. Endocrinology · 2014Review
- Invasive adenoma and pituitary carcinoma: a SEER database analysis.Neurosurgical review · 2014Article
- Molecular status of pituitary carcinoma and atypical adenoma that contributes the effectiveness of temozolomide.Medical molecular morphology · 2014Review
- Treatment of pituitary carcinomas and atypical pituitary adenomas: a review.Neurologia medico-chirurgica · 2014Review
- Aggressive tumors and difficult choices in acromegaly.Pituitary · 2014Review
- New avenues in the medical treatment of Cushing's disease: corticotroph tumor targeted therapy.Journal of neuro-oncology · 2013Review
- A differential diagnosis of inherited endocrine tumors and their tumor counterparts.Clinics (Sao Paulo, Brazil) · 2013Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 4 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Temozolomide is an alkylating agent used in the treatment of gliomas and, more recently, aggressive pituitary adenomas and carcinomas. Temozolomide methylates DNA and, thereby, has antitumor effects. O6-methylguanine-DNA methyltransferase, a DNA repair enzyme, removes the alkylating adducts that are induced by temozolomide, thereby counteracting its effects. A Medline search for all of the available publications regarding the use of temozolomide for the treatment of pituitary tumors was performed. To date, 46 cases of adenohypophysial tumors that were treated with temozolomide, including 30 adenomas and 16 carcinomas, have been reported. Eighteen of the 30 (60%) adenomas and 11 of the 16 (69%) carcinomas responded favorably to treatment. One patient with multiple endocrine neoplasia type 1 and an aggressive prolactin-producing adenoma was also treated and demonstrated a good response. No significant complications have been attributed to temozolomide therapy. Thus, temozolomide is an effective treatment for the majority of aggressive adenomas and carcinomas. Evidence indicates that there is an inverse correlation between levels of O6-methylguanine-DNA methyltransferase immunoexpression and therapeutic response. Alternatively, high-level O6-methylguanine-DNA methyltransferase immunoexpression correlates with an unfavorable response. Here, we review the use of temozolomide for treating pituitary neoplasms.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.